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Introduction
Hashimoto's thyroiditis (HT), also known as chronic 
lymphocytic thyroiditis or chronic autoimmune thyroiditis, is
the most common form of thyroiditis in childhood (1,2). The
pathophysiology of the disease can be summarized as 
follows: triggering of humoral immunity by the abnormal 
stimulation of T-lymphocytes and consequent destruction of
thyroid epithelial cells by chemotaxis, autoantibodies and
inflammatory cascade. The degradation of the cells may be
compensated by the increased thyroid-stimulating hormone
(TSH) levels and the hyperplasia of epithelial cells. If not 
treated, HT may lead to retardation in growth and 
development, resulting in short stature, decline in school,
performance, and anemia (1,2,3,4,5,6,7,8).
Studies regarding the clinical course of the disease in
childhood are quite limited. Discussions are mainly focused
on whether subclinical hypothyroidism should be treated or
not. Although there are accepted criteria for the treatment 
of HT in adults, there are no generally accepted treatment
guidelines for children. Nonetheless, many pediatric 
endocrinologists believe that subclinical hypothyroidism
should be treated in childhood, at a time when growth and
development have not yet been completed. However, the
number of studies investigating  the effect of therapy on the
clinical course of the disease in childhood is  limited
(2,4,6,7,8).
The aim of the present study was to observe the clinical
course of HT in children and adolescents and to determine
the effects of levothyroxine treatment on the clinical course,
on antibody titers and on growth.  
ABS TRACT
Ob jec ti ve: The aim of this study was to evaluate the clinical course of
Hashimoto’s thyroiditis (HT) in children and adolescents and the effects of
levothyroxine therapy on the clinical course and laboratory findings.  
Methods: The clinical and laboratory data of 101 patients with HT  at 
presentation and during a three-year follow-up period were retrospectively
evaluated using patient records. 
Results: The mean age of the patients at the time of diagnosis was 12.3±2.90
years  and female/male ratio was  5.7/1. The complaint at the time of 
hospital presentation was goiter in 57.8% of the patients. At baseline, 36.7%
of the patients were euthyroid, whereas 32.7% had subclinical 
hypothyroidism, 16.6 % of subjects were evaluated as hypothyroid. Twelve of
the 28 patients who were initially euthyroid and not receiving therapy 
developed subclinical or overt hypothyroidism during the first 18 months of the
follow-up period and were started on thyroid medication. At presentation, the
mean anti-thyroglobulin (anti-Tg) and anti-thyroperoxidase antibody levels
were 450±725 IU/mL and 392±428 IU/mL, respectively and at the end of the 
follow-up period, a significant decrease was observed in the anti-Tg levels of
patients receiving levothyroxine from the beginning.   
Conclusions: Thyroid functions of the patients with HT should be monitored
periodically for hypothyroidism. Levothyroxine therapy may positively affect
the clinical course of the disease and the antibody titers. 
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The outpatient records of 101 children and adolescents
younger than 18 years of age, who presented to the Pediatric
Endocrinology Outpatient Clinic of Ege University School of
Medicine between 2002 and 2006, were evaluated 
retrospectively. HT patients who had regularly attended the
scheduled visits for at least two years were included in 
the study. Patients who had a history of a syndrome or 
chromosome abnormality, premature birth or any chronic
disease were excluded.  The diagnosis of HT was based on
ultrasonography (US) and laboratory criteria, and mainly on
detection of antithyroid antibodies. Free triiodothyronine
(fT3), free thyroxine (fT4), TSH,  anti-thyroperoxidase 
(anti-TPO) and anti-thyroglobulin (anti-Tg) antibody levels
were measured. In patients with a diagnosis of HT,  in 
addition to clinical and US findings, the anti-TPO antibody
titers were greater than 200 IU/mL.  Age and gender of 
the patients, as well as their complaints at the time of 
presentation, family history of thyroid disease, concomitant
diseases, and birth weight were recorded. The anthropometric
measurements, pubertal stage and physical examination
findings of the patients, their antithyroid antibody levels,
results of thyroid imaging studies, drug treatment regimen,
fT3, fT4 and TSH levels and anti-TPO and anti-Tg antibody
levels at presentation and during follow-up were also 
recorded. The relationship between antibody levels and 
thyroid hormone replacement therapy was evaluated.
The findings were analyzed by classifying the data as 
"data at presentation", "data in the 1st follow-up period" 
(6-18 months), and "data in the 2nd follow-up period" (18-36
months). Height, weight, and body mass index (BMI) 
standard deviation scores (SDS) were calculated according
to the reference values defined for Turkish children by Neyzi
et al (9).
Laboratory analysis of fT3, fT4 and TSH levels was done
with commercial test kits (Roche Cobas®) using Elecsys
2010® analyzer every 3-6 months. The corresponding 
normal values for the 2.5th and 97.5th percentiles of fT3, fT4
and TSH were 2.0-4.4 pg/mL, 0.93-1.7 ng/dL, and 0.27-4.2
µIU/mL, respectively. 
The patients were evaluated as euthyroid, subclinical
hypothyroid, hypothyroid, subclinical hyperthyroid, or 
hyperthyroid,  according to their fT4 and TSH levels. The HT
subjects were classified to have subclinical hypothyroidism if
they had an elevated serum TSH (TSH >4.7 mIU/mL) 
and normal fT4 concentrations (fT4: 0.82-1.87 ng/dL). If an
elevated serum TSH concentration was associated with a
decreased fT4 concentration, the patient was considered as
an overt hypothyroid. Those with low TSH and elevated 
thyroid hormone levels were accepted as cases of 
hyperthyroidism and those with low TSH and normal thyroid
hormone levels as subclinical hyperthyroidism.
Anti-Tg and anti-TPO antibody measurements were
done using Immulite 2000® kits and Siemens® analyzer
every 6-12 months. The 95th percentile values for anti-Tg
and anti-TPO antibody levels were 40 IU/mL and 35 IU/mL,
respectively.
US examinations were performed by a radiologist, using
high-frequency US. The echogenicity and the size of the 
thyroid gland, presence of thyroid nodules and the lymph
nodes around the gland were evaluated. Thyroid gland 
volume was calculated using the formula proposed 
by Delange et al (10), by multiplying the height, width and
thickness of both lobes of the gland with 0.479. The volume
of the thyroid gland was compared with the reference values
proposed by the World Health Organization in 1997 (11). 
Levothyroxine was initiated in patients with subclinical
hypothyroidism, overt hypothyroidism and also in goitrous
(on US) euthyroid patients. The changes in antibody titers on
levothyroxine therapy, clinical response to the therapy, 
US examination findings during follow-up, and the 
relationship between dose increment and antibody titers
were retrospectively investigated.
The study was reviewed and approved by the Ege
University Ethics Committee. The authors confirmed in 
writing that they have complied with the World Medical
Association Declaration of Helsinki regarding ethical conduct
of research involving human subjects and/or animals.
Statistical Analyses
After the data were transferred to digital media,
Statistical Package for the Social Sciences (SPSS) for
Windows (version 16.0; SPS Inc., Chicago, IL, USA) was
used for analysis. Mann-Whitney U-test, repeated-measure
test and the Kruskal-Wallis test were used for comparisons.
Frequencies were compared using the Chi-square (χ2) test.
A p-value of less than 0.05 was considered to be significant
in all tests.
Results
Of the 101 patients included in the study, 86 were girls
and 15 were boys. Female/male ratio was 5.7/1. The mean
age of the patients at the time of diagnosis was 12.3±2.9
years (range: 4.4-17.9). The mean ages of the male and
female patients at the time of diagnosis were 13.0±2.4 and
12.2±3.0 years, respectively. 
The most common complaint at presentation was
swelling in the neck (58%), followed by nervousness (18%),
dermatological problems (13%), and hair loss (8%).
Thyroid function impairment and/or goiter were present
in the mother, father or siblings of 33% of male and 28% of
female patients.
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presentation were 0.10±1.15, 0.01±1.30 and 0.08±1.15,
respectively.
At presentation, the laboratory findings of 36.7% of the
patients were consistent with euthyroidism, those of 32.7%
with subclinical hypothyroidism. 16.6% of subjects 
were evaluated as hypothyroid, 7.9% as having subclinical
hyperthyroidism, and 5.9% as having hyperthyroidism (Table 1).
At presentation, the mean anti-Tg and anti-TPO antibody
levels were 450±725 IU/mL and 392±428 IU/mL, respectively. 
Results of the first follow-up period
Of the 96 patients who continued to attend the clinic after
the first follow-up period (350±137 days), 68 (70%) were
receiving treatment, while 28 were being followed without
treatment. Levothyroxine was discontinued in two patients
during the follow-up, and five patients were lost to follow-up.
Anti-Tg and anti-TPO antibody values of the 28 cases
who were not receiving treatment were 427±780 IU/mL and
257±374 IU/mL, respectively. The antibody levels of this
group were compared with those of the group of 68 patients
who were receiving treatment and were on regular follow-up
from the beginning of the study. In both groups, anti-Tg 
antibody values decreased, whereas anti-TPO antibody 
values showed an increase (Table 2). 
The changes which occurred in anti-Tg and anti-TPO
antibody values over the first year of follow-up showed no
significant differences between the two groups (p=0.35 
for anti-Tg and p=0.09 for anti-TPO). There also were no 
significant difference in terms of height, weight and BMI SDS
changes between the two groups (p>0.05).
In our study, 68 of our 101 patients were receiving 
treatment at the end of the first follow-up period (6-18
months). Of these patients, seventeen were hypothyroid and
33 had subclinical hypothyroidism. Whereas 36.7% of
patients who had been receiving therapy at presentation
were euthyroid and 32.7% had subclinical hypothyroidism,
these rates changed to 66.7% and 13.5%, respectively, after
the first follow-up period (Table 3). 
The patients who were on thyroid treatment were 
receiving a mean levothyroxine dose of 1.82±0.205 mg/kg at
the time of presentation and the dose was nearly the same
(1.9±0.88 mg/kg) after the first follow-up period.
Results of the second follow-up period
Ninety-six patients in the first follow-up period continued
to be followed in the second follow-up period. In this period,
12 (42.8%) of the 28 patients who were being followed-up
without any treatment in the first follow-up period developed
subclinical hypothyroidism and were started on thyroid 
treatment.  No statistically significant difference was found in
terms of anti-Tg and anti-TPO antibody values and 
anthropometric measurements between these 12 patients
who received treatment after the first follow-up period and
16 patients who continued their follow-up without any 
treatment.
In the second follow-up period, the decrease in anti-Tg
antibody values in  the treated group  was significant
(p=0.01). However, the mean anti-TPO antibody values
remained high despite therapy (Table 4).
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Tab le  1. Thyroid status of the patients at presentation
Females Males Total
n% n % n%
Hypothyroid 16 18.7 1 6.7 17 16.8
Subclinical 25 29.0 8 53.3 33 32.7
hypothyroid
Euthyroid 33 38.4 4 26.7 37 36.7
Subclinical 8 9.3 0 0 8 7.9
hyperthyroid
Hyperthyroid 4 4.6 2 13.3 6 5.9
Total 86 100 15 100 101 100
Tab le  2. Comparison of antibody levels in the treated  and non-treated
groups at the end of the first follow-up period
Tab le  3.  Thyroid status of the patients at presentation and at the end of
the first follow-up period
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At At the end   p
presentation of the 1st
follow-up period
Treated anti-Tg  (IU/mL) 438±747 322±475 0.41
(n=68) anti-TPO (IU/mL) 413±433 550±688 0.31
Non- treated anti-Tg (IU/mL) 620±881 427±780 0.97
(n=28) anti-TPO (IU/mL) 247±348 257±374 0.73
anti-Tg: anti-thyroglobulin, anti-TPO: anti-thyroperoxidase
At presentation At the end of 1st
follow-up period
n% n%
Hypothyroid 17 16.8 16 16.7
Subclinical 33 32.7 13 13.5
hypothyroid
Euthyroid 37 36.7 64 66.7
Subclinical 8 7.9 2 2.1
hyperthyroid
Hyperthyroid 6 5.9 1 1.0
Total 101 100 96 100No significant difference was found in terms of weight,
height, and BMI SDS values between the treated group and
the group not receiving therapy. 
Eighty-nine of 101 cases underwent US and thyromegaly
was detected in 31 (34%) of them. Follow-up US was 
performed in 48 cases after two years. Eight of 18 patients,
who had thyromegaly and were receiving treatment at 
presentation, underwent follow-up US, and the size of the
thyroid gland was found to be decreased or reverted to 
normal size in 7 of these 8 patients.
No remarkable decrease in the size of the thyroid gland
was found in the group not receiving therapy. Thyromegaly
was observed in the repeated US of three cases that did not
have thyromegaly initially.
Discussion
Although autoimmune thyroiditis in adults has 
been extensively investigated, studies on children and 
adolescents are limited. The natural course of juvenile
autoimmune thyroiditis is quite variable (8,12,13).
Nonetheless, follow-up studies on adults indicate a shift to
subclinical  hypothyroidism and hypothyroidism from 
euthyroidism (14,15,16). In the four-year follow-up study
conducted by Radetti et al (8), the majority of euthyroid
patients remained euthyroid, whereas those with 
subclinical hypothyroidism were observed to develop clinical
hypothyroidism. Researchers suggest that TSH levels at the
time of presentation are important in signaling the clinical
course of the disease (15,16). Whickham, in a 20-year 
follow-up study, found the annual risk of spontaneous
hypothyroidism as 0.35% (14).
Moore et al (17) followed 17 children with euthyroid 
juvenile autoimmune thyroiditis for 52 months and found that
only one required permanent treatment, and claimed that
therapy does not affect the clinical prognosis in juvenile
autoimmune thyroiditis. In another study conducted by
Gruñeiro de Papendieck et al (18) in 16 children, nine of 
the children became euthyroid, two had subclinical 
hypothyroidism that remained unchanged, and five children
shifted to hypothyroidism. In our study, 37 patients were
receiving treatment at presentation and 64 were not under
treatment. Overall, 36% of our 101 patients were euthyroid,
33% had subclinical hypothyroidism, and 17% had 
hypothyroidism. These rates, in respective order, were 24%,
33% and 43% in the study conducted by Gopalakrishnan et al
(12) and 21%, 43% and 37% in the study conducted by de
Vries et al (19). 
The majority of long-term follow-up studies including
quantitative thyroid antibody measurements have been 
performed on a small sample of adults (20,21,22,23,24,
25,26,27). Mariotti et al (25) , in their study which comprised
77 hypothyroid and 21 euthyroid patients who had been 
on levothyroxine therapy for 12 to 18 months, found a 
significant decrease in the anti-TPO levels of 15 patients.
Romaldini et al (26) observed a 78% decrease in the 
anti-TPO levels and an 81% reduction in thyroid volume in
10 patients after six months of therapy. The researchers
highlighted that treatment led to a significant decrease in the
anti-Tg and anti-TPO values of patients with hypothyroidism,
while only a non-significant decrease was noted in those
with subclinical hypothyroidism. In their study conducted on
38 patients, Schmidt et al (27) reported a decrease in 
the anti-TPO values in the majority of patients receiving
levothyroxine; however, these same authors reported 
negative anti-TPO titers in only 16% of the patients at the
end of the 50-month follow-up period. They observed a 
fluctuation in the anti-TPO levels of 8% of the patients
despite therapy, and consequently, the levels were
increased in some patients. Hegedüs et al (28) found no 
significant decrease in anti-TPO values after two years of 
follow-up in a 13-patient study group. In this present study,
the mean anti-Tg levels showed a significant decreased in
the group receiving treatment. However, our sample size
was too small to state that levothyroxine treatment
decreased the anti-Tg levels.  We found a decrease in 
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Tab le  4.  Comparison of antibody levels in the treated  and non-treated groups at presentation and at the end of the first and second follow-up periods 
At presentation At the end of the 1st  At the end of the 2nd  p
follow-up period follow-up period
Treated  (n=80) anti-Tg (IU/mL) 472±795 343±504 252±395 0.01
anti-TPO (IU/mL) 424±437 468±342 560±374 0.31
Non-treated (n=16) anti-Tg (IU/mL) 488±739 489±796 136±113 0.26
anti-TPO (IU/mL) 184±171 157±193 231±319 0.49
anti-Tg: anti-thyroglobulin, anti-TPO: anti-thyroperoxidase
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therapy.  Padberg et al (22) conducted a study on 21 cases
and found a decrease in the anti-TPO values of patients with
euthyroid HT who were receiving treatment, while no
decrease was observed in patients not receiving therapy.
The decrease observed in anti-Tg values in the same study
was not significant.
Despite the fact that growth retardation is one of the
most common complaints at presentation in patients with
HT, no abnormality in terms of height, weight and BMI SDS
values was observed in the present study. This may be
attributed to the fact that overall rate of hypothyroidism was
6.1% to 16.8% in this group of patients and that most of
these patients were rendered euthyroid during the long-term
follow-up.
In our study, due to the limited number of patients on
levothyroxine treatment who had been followed by US, the 
findings pertaining to regression of the thyromegaly are 
not conclusive. Scarpa et al (29) studied 50 euthyroid 
non-goitrous children and adolescents with HT for 2 years by
thyroid function tests and US and reported a lower thyroid 
volume SDS in the treatment group as compared to the 
controls. Svensson et al (30) reported that levothyroxine 
treatment significantly reduced the thyroid volume in 
pediatric patients with goitrous, hypothyroid and euthyroid HT. 
In conclusion, thyroid functions should be monitored
periodically for hypothyroidism in all children and adolescents
with HT, including those who are initially euthyroid or have
subclinical hypothyroidism. Most patients who are not
receiving treatment at the time of presentation may require
treatment subsequently. Levothyroxine therapy may have
beneficial effects on the clinical course of the disease and on
antibody titers. Randomized controlled studies on large
pediatric patient series are needed.
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